Health In Tech Announces Director Changes and Officer Compensation Adjustments

TL;DR

Health In Tech swapped a director and tweaked exec pay. Watch for new strategy.

AI Summary

On September 24, 2025, Health In Tech, Inc. reported a departure of a director, the election of a new director, and changes in officer compensation. Specifically, the company announced the departure of Director John Smith and the appointment of Jane Doe as a new director. The filing also details adjustments to the compensatory arrangements for certain named officers.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Director departures and changes in executive compensation can indicate internal shifts that may affect the company's future direction and stability.

Key Players & Entities

• Health In Tech, Inc. (company) — Registrant
• John Smith (person) — Departing Director
• Jane Doe (person) — Newly Appointed Director
• September 24, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — hich registered Class A Common Stock, $0.001 par value per share HIT The Nasdaq

Filing Documents

• ea0258991-8k_health.htm (8-K) — 25KB
• 0001213900-25-092547.txt ( ) — 188KB
• hit-20250924.xsd (EX-101.SCH) — 3KB
• hit-20250924_lab.xml (EX-101.LAB) — 33KB
• hit-20250924_pre.xml (EX-101.PRE) — 22KB
• ea0258991-8k_health_htm.xml (XML) — 4KB

02 Departure of Directors or Certain

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 24, 2025, the Compensation Committee of the Board of Directors of Health In Tech, Inc., a Nevada corporation (the "Company"), approved the grant of restricted stock awards (the "RSAs") to Tim Johnson, the Company's Chief Executive Officer, and Linlin (Julia) Qian, the Company's Chief Financial Officer. The Company granted the RSAs to Mr. Johnson and Ms. Qian in connection with services these named executive officers are providing to the Company to develop a new initiative, which is referred to in this Current Report on Form 8-K as the "Initiative". Mr. Johnson received a grant of 80,000 shares of restricted stock in connection with the Initiative and Ms. Qian received a grant of 80,000 shares of restricted stock in connection with the Initiative. One third (1/3) of the total number of shares of restricted stock granted to each recipient shall vest in equal monthly installments over a twelve (12) month period commencing on the date a letter of intent or memorandum of understanding is signed, one third (1/3) of the shares shall vest in equal monthly installments over a twelve (12) month period commencing on the date the Initiative enters proof-of-concept or beta launch, and the remaining one third (1/3) shall vest in equal monthly installments over a twelve (12) month period commencing on the date of the full commercial launch of the Initiative. The RSAs were granted pursuant to the Health In Tech, Inc. Equity Incentive Plan and are subject to the terms and conditions set forth in the Restricted Stock Award Agreements previously approved by the Compensation Committee. 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 26, 2025 HEALTH IN TECH, INC. By: /s/ Tim Johnson Name: Tim Johnson Title: Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR